{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:14Z","timestamp":1791212414163,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s00108-007-1804-2","type":"journal-article","created":{"date-parts":[[2007,2,7]],"date-time":"2007-02-07T13:25:15Z","timestamp":1170854715000},"page":"372-381","source":"Crossref","is-referenced-by-count":7,"title":["Therapie des follikul\u00e4ren Lymphoms","Therapy of follicular lymphoma"],"prefix":"10.1007","volume":"48","author":[{"given":"C.","family":"Buske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unterhalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hiddeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"1804_CR1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0145-2126(06)80003-2","volume":"30","author":"Buske","year":"2006","unstructured":"Buske C, Hiddemann W (2006) Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res 30 (Suppl 1): S11\u2013S15","journal-title":"Leuk Res"},{"key":"1804_CR2","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M et al. (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108: 1504\u20131508","journal-title":"Blood"},{"key":"1804_CR3","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2004-10-3920","volume":"105","author":"Deconinck","year":"2005","unstructured":"Deconinck E, Foussard C, Milpied N et al. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105: 3817\u20133823","journal-title":"Blood"},{"key":"1804_CR4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/jco.2005.23.16_suppl.6528","volume":"23","author":"Dreyling","year":"2005","unstructured":"Dreyling M, Forstpointner R, Ludwig WD et al. (2005) Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma- follow-up of a randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 567\u00a0s","journal-title":"J Clin Oncol"},{"key":"1804_CR5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","volume":"86","author":"Dreyling","year":"2006","unstructured":"Dreyling M, Trumper L, von Schilling C et al. (2006) Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma-role of radioimmunotherapy. Ann Hematol 86: 81\u201387","journal-title":"Ann Hematol"},{"key":"1804_CR6","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M et al. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 108: 4003\u20134008","journal-title":"Blood"},{"key":"1804_CR7","doi-asserted-by":"crossref","unstructured":"Foussard C, Mounier N, Van Hoof A et al. (2006) Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol, ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 24, No 18S (Abstract 7508)","DOI":"10.1200\/jco.2006.24.18_suppl.7508"},{"key":"1804_CR8","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB et al. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103: 4416\u20134423","journal-title":"Blood"},{"key":"1804_CR9","doi-asserted-by":"crossref","first-page":"484a","DOI":"10.1182\/blood.V108.11.484.484","volume":"108","author":"Herold","year":"2006","unstructured":"Herold M, Haas A, Srock S et al. (2006) Addition of rituximab to first-line MCP (mitoxantrone, clorambucil, prednisolone) chemotherapy prolongs survival in advanced follicular lymphoma: 4 year follow-up results of a phase III trial of the East German Study Group Hematology and Oncology (OSHO#39). Blood 108: 484a","journal-title":"Blood"},{"key":"1804_CR10","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725\u20133732","journal-title":"Blood"},{"key":"1804_CR11","doi-asserted-by":"crossref","first-page":"349a","DOI":"10.1182\/blood.V106.11.349.349","volume":"106","author":"Hochster","year":"2005","unstructured":"Hochster HS, Weller E, Gascoyne RD et al. (2005) Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Session Blood 106: 349a","journal-title":"Session Blood"},{"key":"1804_CR12","first-page":"tumours","volume":"tumours","author":"Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H et al. (Eds) (2001) World Health Organisation classification of tumours: tumours of the haemopoitic and lymphoid tissues. IARC Press, Lyon","journal-title":"World Health Organisation classification of"},{"key":"1804_CR13","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E et al. (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104: 2667\u20132674","journal-title":"Blood"},{"key":"1804_CR14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105: 1417\u20131423","journal-title":"Blood"},{"key":"1804_CR15","doi-asserted-by":"crossref","first-page":"408a","DOI":"10.1182\/blood-2003-03-1005","volume":"102","author":"Radford","year":"2003","unstructured":"Radford JA, Ketterer N, Sebban C et al. (2003) Ibritumomab tiuxetan (Zevalin TM) therapy is feasible and safe for the treatment of patients with advanced B-cell follicular lymphoma: interim analysis for safety of a multicenter, phase III clinical trial [abstract]. Blood 102: 408a; 1484","journal-title":"Blood"},{"key":"1804_CR16","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","unstructured":"Sebban C, Mounier N, Brousse N et al. (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Blood 108: 2540\u20132544","journal-title":"Blood"},{"key":"1804_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/jco.2005.23.16_suppl.579","volume":"23","author":"Shipley","year":"2005","unstructured":"Shipley DL, Greco FA, Spigel DR et al. (2005) Rituximab with short duration chemotherapy followed by 90 Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial [abstract]. Proc Am Soc Clin Oncol 23: 579\u00a0s; 6577","journal-title":"Proc Am Soc Clin Oncol"},{"key":"1804_CR18","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"Oers","year":"2006","unstructured":"Oers MH van, Klasa R, Marcus RE et al. (2006) Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108: 3295\u20133301","journal-title":"Blood"},{"key":"1804_CR19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/bjc.1994.213","volume":"69","author":"Vaughan","year":"1994","unstructured":"Vaughan Hudson B, Vaughan Hudson G, MacLennan KA et al. (1994) Clinical stage 1 non-Hodgkin\u2019s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69: 1088\u20131093","journal-title":"Br J Cancer"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1804-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-007-1804-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-007-1804-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T01:22:25Z","timestamp":1587345745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-007-1804-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["1804"],"URL":"https:\/\/doi.org\/10.1007\/s00108-007-1804-2","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}